

Basal cell carcinoma - Pipeline Insight, 2021

<https://marketpublishers.com/r/B75D160176DEN.html>

Date: October 2021

Pages: 70

Price: US\$ 2,000.00 (Single User License)

ID: B75D160176DEN

Abstracts

This report can be delivered to the clients within 72 hours

DelveInsight's, "Basal cell carcinoma - Pipeline Insight, 2021," report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Basal cell carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Basal cell carcinoma Understanding

Basal cell carcinoma: Overview

Basal cell carcinoma (BCC) is a common, locally invasive, keratinocyte cancer (also known as nonmelanoma cancer). It is the most common form of skin cancer. BCC is also known as rodent ulcer and basalioma. The main characteristics are: Slowly growing plaque or nodule, Skin colored, pink or pigmented, Varies in size from a few millimeters to several centimeters in diameter, Spontaneous bleeding or ulceration. Ultraviolet (UV) rays from the sun or from a tanning bed are the main cause of basal cell carcinoma. The goal of treatment for basal cell carcinoma is to remove the cancer completely. The clinical appearance, size, site, and histologic subtype determine choice of treatment: curettage and electrodesiccation, surgical excision, cryosurgery, topical chemotherapy (imiquimod or 5-fluorouracil) and photodynamic therapy, or, occasionally,

radiation therapy. Large or recurrent basal cell cancers are treated best with Mohs' surgery (a specialized type of microscopically controlled surgery).

'Basal cell carcinoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Basal cell carcinoma pipeline landscape is provided which includes the disease overview and Basal cell carcinoma treatment guidelines. The assessment part of the report embraces, in depth Basal cell carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Basal cell carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Basal cell carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Basal cell carcinoma.

Basal cell carcinoma Emerging Drugs Chapters

This segment of the Basal cell carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Basal cell carcinoma Emerging Drugs

Patidegib: PellePharm

Patidegib is an investigational small molecule that inhibits hedgehog signaling. It is a topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently evaluated in

Phase III clinical trials for the treatment of BCCs.

AIV001: AiViva BioPharma

AIV001 is a novel formulation of a multi-kinase inhibitor combined with AiViva's proprietary delivery technology, designed for prolonged drug release via intradermal treatment. AIV001 targets multiple pathways to reduce fibroplasia in overlapping phases of wound healing and scarring; targets VEGFR to limit the inflammation and fibrosis associated with rosacea; and inhibits or reduces neovascularization and cell proliferation associated with certain cancers. AIV001 is in Phase I/II clinical studies for the treatment of patients with Basal Cell Carcinoma.

Further product details are provided in the report.....

Basal cell carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Basal cell carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Basal cell carcinoma

There are approx. 25+ key companies which are developing the therapies for Basal cell carcinoma. The companies which have their Basal cell carcinoma drug candidates in the most advanced stage, i.e. Phase III include, PellePharm.

Phases

DelveInsight's report covers around 25+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Basal cell carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Basal cell carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Basal cell carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Basal cell carcinoma drugs.

Basal cell carcinoma Report Insights

- Basal cell carcinoma Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Basal cell carcinoma Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Basal cell carcinoma drugs?

How many Basal cell carcinoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Basal cell carcinoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Basal cell carcinoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Basal cell carcinoma and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

PellePharm

MedC Biopharma Corporation

AiViva BioPharma

MediWound

Kintara Therapeutics

IO Biotech

Sirnaomics

Aresus Pharma

Epitome Pharmaceuticals

Transgene

Senhwa Biosciences

Palvella Therapeutics

Suzhou Kintor Pharmaceuticals

Leaf Vertical

Key Products

AIV001

Patidegib

MDC-2060

MWPC 005

Rostaporfin

IO103

STP 705

Polyphenon E

AIV 001

TG 1042

Silmitasertib

Sirolimus topical

GT 1708F

Cannabidiol

Contents

Introduction

Executive Summary

Basal cell carcinoma: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Basal cell carcinoma – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Patidegib: PellePharm

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

IO103: IO Biotech

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I/II)

Comparative Analysis

AIV001: AiViva BioPharma

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Cannabidiol: Leaf Vertical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Basal cell carcinoma Key Companies
Basal cell carcinoma Key Products
Basal cell carcinoma- Unmet Needs
Basal cell carcinoma- Market Drivers and Barriers
Basal cell carcinoma- Future Perspectives and Conclusion
Basal cell carcinoma Analyst Views
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Basal cell carcinoma

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Basal cell carcinoma

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Basal cell carcinoma - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/B75D160176DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B75D160176DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970